

**Table 1 .**  
**Baseline characteristics of the patients cohorts by age groups with**  
**canagliflozin 100 mg (CANA100) and canagliflozin 300 mg (CANA300).**

	CANA100			CANA300		
	<65 years (n 176)	≥65 years (n 103)	p	<65 years (n 177)	≥65 years (n 127)	p
Follow-up time (months)*	9.1 (5.0-20.3)	9.2 (5.9-22.3)	0.402	17.5 (7.9-30.4)	14.0 (6.7-24.3)	0.013
Gender (male/female)	54/46	56.3/43.7	0.705	57.1/42.9	54.3/45.7	0.636
Age (years)	52.8 (10.0)	71.5 (4.9)	<0.0001	54.5 (8.2)	70.3 (3.5)	<0.0001
Duration of T2DM (years)*	8.0 (3.7-13.4)	12.0 (8.4-17.8)	<0.0001	10.1 (5.8-15.2)	15.9 (11.2-21.0)	<0.0001
HbA1c (%)	8.11 (1.60)	7.94 (1.40)	0.375	7.48 (1.24)	7.55 (0.93)	0.572
Patients with HbA1c>7%	74.0	76.2	0.677	67.2	76.4	0.083
Fasting plasma glucose (mg/dl)	167.1 (61.8)	156.8 (49.1)	0.131	144.4 (38.1)	142.6 (32.9)	0.664
Weight (kg)	99.2 (22.1)	87.5 (16.9)	<0.0001	97.6 (22.1)	84.2 (16.7)	<0.0001
BMI (kg/m2)	35.8 (7.2)	33.1 (6.8)	0.003	35.6 (7.7)	32.0 (6.9)	0.002
SBP(mmHg)	137.8 (20.3)	139.7 (20.0)	0.485	136.3 (13.7)	135.2 (15.6)	0.560
DBP (mmHg)	80.4 (10.0)	77.3 (10.0)	0.018	79.8 (10.8)	73.6 (10.2)	<0.0001
eGFR (mL/min/1.73 m2)	92.4 (14.3)	76.6 (15.0)	<0.0001	90.4 (16.6)	77.5 (14.5)	<0.0001
Microalbuminuria (mg/g Cr)*	6.0 (4.0-31.1)	9.8 (4.3-37.0)	0.417	7.2 (0-25.4)	8.8(0-27.6)	0.715
Diabetic renal disease (%)						

Stage G0/G1	67.9	24.7	<0.0001	62.9	27.6	<0.0001
Stage G2	30.9	56.7		32.9	56.7	
Stage G3a	1.2	17.5		3.0	15.7	
Stage G3b	0	1.0		0.6	0	
Stage G4 – G5	0	0		0.6	0	
Stage A1	73.9	75.0	0.179	80.0	78.4	0.773
Stage A2	22.8	15.6		16.8	19.6	
Stage A3	3.3	9.4		3.2	2.1	
Hypertension	68.2	82.5	0.009	81.9	85.8	0.365
Hypercholesterolaemia	75.0	88.3	0.007	87.6	95.3	0.022
Hypertriglyceridaemia	44.6	31.1	0.026	56.5	45.2	0.053
Combined hyperlipidaemia	38.3	31.1	0.225	51.4	45.2	0.289
Diabetic renal disease	18.8	24.3	0.273	26.6	29.1	0.62
Diabetic neuropathy	7.4	8.7	0.686	8.5	15.7	0.05
Coronary artery disease	8.0	9.8	0.597	5.6	17.3	0.001
Stroke	2.8	5.8	0.216	3.4	3.9	0.801
Peripheral artery disease	1.7	5.8	0.06	6.8	12.6	0.084
Arrhythmias	1.1	10.7	<0.0001	4.0	5.5	0.523
Heart failure	1.1	2.9	0.280	2.8	3.1	0.869



Differences between age groups were not statistically significant, except for hypoglycaemias in the C300 cohort (p 0.033)

AEs: Adverse Events

\*Withdrawals in the CANA100 cohort other than switching to CANA300.